OPC-6535(Tetomilast)

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Co., Ltd.

Conditions

Colitis, UlcerativeCrohn Disease

Phase 2

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

TerminatedNCT00317356

Otsuka Pharmaceutical Co., Ltd.Colitis, Ulcerative

Start: 2006-05-31End: 2007-08-31Updated: 2021-04-30

A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease

TerminatedNCT00317369

Otsuka Pharmaceutical Co., Ltd.Crohn Disease

Start: 2006-05-31End: 2007-08-31Updated: 2021-02-15